carbon monoxide has been researched along with Diabetes Mellitus in 25 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydrogen sulfide (H2S)has emerged as the third gasotransmitter following the nitric oxide and carbon monoxide in the body, and plays an important role in both physiology and pathophysiology." | 6.58 | [Research Advances in Hydrogen Sulfide and Diabetes Mellitus as Well as Diabetic Complications]. ( Gu, Y; Ji, Y; Meng, GL; Xie, LP, 2018) |
| " Two chemical markers, cotinine in plasma and carbon monoxide (CO) in expired air, validated self-reports concerning smoking cessation." | 3.71 | Are patients truthful about their smoking habits? A validation of self-report about smoking cessation with biochemical markers of smoking activity amongst patients with ischaemic heart disease. ( Berndt, AK; From Attebring, M; Herlitz, J; Hjalmarson, A; Karlsson, T, 2001) |
| " Cough was the most common adverse event; however, there was no difference in incidence between the AIR insulin (15." | 2.74 | Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12-month, randomized, noninferiority trial. ( Ang, E; Berclaz, PY; Ferguson, JA; Heilmann, CR; Lawrence, MK; Tobian, JA; Webb, DM, 2009) |
| "Hydrogen sulfide (H2S)has emerged as the third gasotransmitter following the nitric oxide and carbon monoxide in the body, and plays an important role in both physiology and pathophysiology." | 2.58 | [Research Advances in Hydrogen Sulfide and Diabetes Mellitus as Well as Diabetic Complications]. ( Gu, Y; Ji, Y; Meng, GL; Xie, LP, 2018) |
| "The analysis of data from a COPD cohort showed no significant differences of CO transport parameters between COPD patients with and without diabetes, if BMI, gender and the reduction in lung volumes were taken into account." | 1.46 | Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. ( Alter, P; Bals, R; Behr, J; Biertz, F; Holle, R; Huber, RM; Jörres, RA; Kahnert, K; Karrasch, S; Lechner, A; Lucke, T; Söhler, S; Stubbe, B; Vogelmeier, C; Wacker, M; Watz, H; Wouters, EF, 2017) |
| "Diabetes mellitus is a disease affecting a lot of organs." | 1.43 | [Lung function in patients with diabetes mellitus]. ( Couraud, S; Fontaine-Delaruelle, C; Luyton, C; Viart-Ferber, C, 2016) |
| " In patients with diabetes, a lower bioavailability of the different gasotransmitters is observed when compared with healthy individuals." | 1.43 | Gasotransmitters in Vascular Complications of Diabetes. ( Greffrath, W; Hammes, HP; Hillebrands, JL; van den Born, JC; van Goor, H, 2016) |
| "However, proteinuria was the only significant independent predictor of DLCO/VA." | 1.30 | Reduction of diffusion capacity for carbon monoxide in diabetic patients. ( Car, N; Drazić, Z; Ljubić, S; Metelko, Z; Roglić, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (40.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leal, EC | 1 |
| Carvalho, E | 1 |
| Chu, HW | 1 |
| Ma, YJ | 1 |
| Huang, ZH | 1 |
| Kashfi, K | 1 |
| Gu, Y | 1 |
| Xie, LP | 1 |
| Meng, GL | 1 |
| Ji, Y | 1 |
| Wegiel, B | 1 |
| Nemeth, Z | 1 |
| Correa-Costa, M | 1 |
| Bulmer, AC | 1 |
| Otterbein, LE | 1 |
| Fontaine-Delaruelle, C | 1 |
| Viart-Ferber, C | 1 |
| Luyton, C | 1 |
| Couraud, S | 1 |
| van den Born, JC | 1 |
| Hammes, HP | 1 |
| Greffrath, W | 1 |
| van Goor, H | 1 |
| Hillebrands, JL | 1 |
| Steiger, C | 1 |
| Hermann, C | 1 |
| Meinel, L | 1 |
| Kahnert, K | 1 |
| Lucke, T | 1 |
| Biertz, F | 1 |
| Lechner, A | 1 |
| Watz, H | 1 |
| Alter, P | 1 |
| Bals, R | 1 |
| Behr, J | 1 |
| Holle, R | 1 |
| Huber, RM | 1 |
| Karrasch, S | 1 |
| Stubbe, B | 1 |
| Wacker, M | 1 |
| Söhler, S | 1 |
| Wouters, EF | 1 |
| Vogelmeier, C | 1 |
| Jörres, RA | 1 |
| Idriss, NK | 1 |
| Blann, AD | 1 |
| Lip, GY | 1 |
| Franco, RS | 1 |
| Ang, E | 1 |
| Lawrence, MK | 1 |
| Heilmann, CR | 1 |
| Ferguson, JA | 1 |
| Tobian, JA | 1 |
| Webb, DM | 1 |
| Berclaz, PY | 1 |
| PAESLACK, V | 1 |
| Gachon, AM | 1 |
| Ghaddab, M | 1 |
| Kitzis, A | 1 |
| Wajcman, H | 1 |
| Dastugue, B | 1 |
| Stevenson, DK | 1 |
| Ostrander, CR | 1 |
| Hopper, AO | 1 |
| Cohen, RS | 1 |
| Johnson, JD | 1 |
| Ljubić, S | 1 |
| Metelko, Z | 1 |
| Car, N | 1 |
| Roglić, G | 1 |
| Drazić, Z | 1 |
| From Attebring, M | 1 |
| Herlitz, J | 1 |
| Berndt, AK | 1 |
| Karlsson, T | 1 |
| Hjalmarson, A | 1 |
| Zamarrón, C | 1 |
| Del Campo, F | 1 |
| Paredes, C | 1 |
| Rodríguez Suárez, JR | 1 |
| Hevelke, G | 1 |
| Sugahara, K | 1 |
| Ushizima, K | 1 |
| Morioka, T | 1 |
| Kato, N | 1 |
| Kawaguchi, K | 1 |
| Bell, D | 1 |
| Collier, DA | 1 |
| Weir, DC | 1 |
| Jennings, PE | 1 |
| Hendy, MS | 1 |
| Barnett, AH | 1 |
| Burge, PS | 1 |
| Mosca, A | 1 |
| Carpinelli, A | 1 |
| Paleari, R | 1 |
| Carenini, A | 1 |
| Bonini, P | 1 |
| Franzini, C | 1 |
| Nikberg, II | 1 |
| Murashko, VA | 1 |
| Leonenko, IN | 1 |
| Desoille, H | 1 |
| Cremer, G | 1 |
| Girard, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD[NCT01245933] | 2,741 participants (Actual) | Observational | 2010-11-30 | Active, not recruiting | |||
| A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma[NCT00157339] | Phase 3 | 299 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for carbon monoxide and Diabetes Mellitus
| Article | Year |
|---|---|
Heme Oxygenase-1 as Therapeutic Target for Diabetic Foot Ulcers.
Topics: Anti-Inflammatory Agents; Antioxidants; Biliverdine; Carbon Monoxide; Diabetes Mellitus; Diabetic Fo | 2022 |
[Research Advances in Hydrogen Sulfide and Diabetes Mellitus as Well as Diabetic Complications].
Topics: Carbon Monoxide; Diabetes Complications; Diabetes Mellitus; Humans; Hydrogen Sulfide; Nitric Oxide | 2018 |
Heme oxygenase-1: a metabolic nike.
Topics: Animals; Biosynthetic Pathways; Carbon Monoxide; Cell Respiration; Diabetes Mellitus; Heme; Heme Oxy | 2014 |
Localized delivery of carbon monoxide.
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Animals; Biliverdine; C | 2017 |
Hemoxygenase-1 in cardiovascular disease.
Topics: Animals; Antioxidants; Bilirubin; Carbon Monoxide; Cardiovascular Diseases; Diabetes Mellitus; Heme | 2008 |
The measurement and importance of red cell survival.
Topics: Anemia; Animals; Biotinylation; Breath Tests; Carbon Monoxide; Chromium Isotopes; Chromium Radioisot | 2009 |
[Etiology and therapy of arteriosclerosis].
Topics: Alcoholism; Arteriosclerosis; Blood Circulation; Carbon Monoxide; Cholestyramine Resin; Diabetes Mel | 1978 |
1 trial available for carbon monoxide and Diabetes Mellitus
| Article | Year |
|---|---|
Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12-month, randomized, noninferiority trial.
Topics: Administration, Inhalation; Adult; Age of Onset; Aged; Asthma; Body Mass Index; Carbon Monoxide; Dia | 2009 |
17 other studies available for carbon monoxide and Diabetes Mellitus
| Article | Year |
|---|---|
A pilot study: effect of erythrocyte lifespan determined by a modified carbon monoxide breath test on glycosylated hemoglobin interpretation.
Topics: Adult; Breath Tests; Carbon Monoxide; Diabetes Mellitus; Erythrocytes; Female; Glycated Hemoglobin; | 2020 |
The role of hydrogen sulfide in health and disease.
Topics: Carbon Monoxide; Diabetes Mellitus; Gasotransmitters; Gastrointestinal Diseases; Gene Expression Reg | 2018 |
[Lung function in patients with diabetes mellitus].
Topics: Adult; Carbon Monoxide; Diabetes Mellitus; Female; Forced Expiratory Volume; Humans; Lung; Male; Mid | 2016 |
Gasotransmitters in Vascular Complications of Diabetes.
Topics: Biological Availability; Carbon Monoxide; Diabetes Mellitus; Diabetic Angiopathies; Gasotransmitters | 2016 |
Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort.
Topics: Aged; Carbon Dioxide; Carbon Monoxide; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Germa | 2017 |
[Diabetes mellitus following carbon monoxide poisoning].
Topics: Carbon Monoxide; Carbon Monoxide Poisoning; Diabetes Mellitus; Humans | 1961 |
Fast fluctuations of glycosylated hemoglobins. I. Implications for the preparation and storage of samples for hemoglobin A1c determinations.
Topics: Carbon Monoxide; Cold Temperature; Diabetes Mellitus; Glycated Hemoglobin; Hemolysis; Humans; In Vit | 1982 |
Pulmonary excretion of carbon monoxide as an index of bilirubin production. IIa. Evidence for possible delayed clearance of bilirubin in infants of diabetic mothers.
Topics: Bilirubin; Carbon Monoxide; Diabetes Mellitus; Female; Humans; Infant, Newborn; Jaundice, Neonatal; | 1981 |
Reduction of diffusion capacity for carbon monoxide in diabetic patients.
Topics: Adult; Carbon Monoxide; Chromatography, Ion Exchange; Chronic Disease; Diabetes Complications; Diabe | 1998 |
Are patients truthful about their smoking habits? A validation of self-report about smoking cessation with biochemical markers of smoking activity amongst patients with ischaemic heart disease.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbon Monoxide; Case-Control Studies; Chi-Square | 2001 |
[Pulmonary diffusion of carbon monoxide in 2 clinical situations: bronchial asthma and diabetes mellitus].
Topics: Aged; Asthma; Carbon Monoxide; Diabetes Mellitus; Diffusion; Female; Humans; Lung; Male; Middle Aged | 2001 |
[Diffusing capacity of the lung and low PaO2 in diabetic patients (author's transl)].
Topics: Adult; Aged; Carbon Monoxide; Diabetes Mellitus; Humans; Middle Aged; Oxygen; Partial Pressure; Pulm | 1979 |
Transfer factor for carbon monoxide in patients with diabetes with and without microangiopathy.
Topics: Carbon Monoxide; Diabetes Mellitus; Diabetic Angiopathies; Humans | 1989 |
Transfer factor for carbon monoxide in patients with diabetes with and without microangiopathy.
Topics: Carbon Monoxide; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Lung; Male; Middle Aged; | 1988 |
Preparation and control of ethylene glycol-stabilized haemolysates for glycated haemoglobin assay.
Topics: Blood Glucose; Buffers; Carbon Monoxide; Diabetes Mellitus; Ethylene Glycol; Ethylene Glycols; Glyca | 1985 |
[Carbon monoxide concentration in the air exhaled by the healthy and the ill].
Topics: Carbon Monoxide; Cardiovascular Diseases; Diabetes Mellitus; Humans; Kidney Diseases; Respiration; S | 1972 |
[On the subject of a supposed blood carbon monoxide of endogenous origin in diabetics].
Topics: Blood; Carbon Monoxide; Diabetes Mellitus; Humans | 1965 |